Tularaemia - Pipeline Review, H2 2020

November 2020 | 46 pages | ID: TE6C9ED4CAFEN
Global Markets Direct

Abstracts

Tularaemia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2020, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.

Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Tularaemia - Overview
Tularaemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tularaemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tularaemia - Companies Involved in Therapeutics Development
Appili Therapeutics Inc
Aradigm Corp (Inactive)
DynPort Vaccine Company LLC
Emergex Vaccines Holding Ltd
EpiVax Inc
Tularaemia - Drug Profiles
ATI-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDBR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRI-011225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularaemia [strain B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularaemia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularaemia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tularemia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tularaemia - Dormant Projects
Tularaemia - Discontinued Products
Tularaemia - Product Development Milestones
Featured News & Press Releases
Jan 28, 2020: Researchers present positive interim data on Appili Therapeutics’ ATI-1701 Biodefense program at 2020 ASM Biothreats
Nov 18, 2019: Researchers present new positive interim data on Appili Therapeutics ATI-1701 biodefense program at 2019 Chemical and Biological Defense Science & Technology Conference
Aug 20, 2019: Researchers to present new data on ATI-1701 at the 2019 Military Health System Research Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Tularaemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Tularaemia - Pipeline by Appili Therapeutics Inc, H2 2020
Tularaemia - Pipeline by Aradigm Corp (Inactive), H2 2020
Tularaemia - Pipeline by DynPort Vaccine Company LLC, H2 2020
Tularaemia - Pipeline by Emergex Vaccines Holding Ltd, H2 2020
Tularaemia - Pipeline by EpiVax Inc, H2 2020
Tularaemia - Dormant Projects, H2 2020
Tularaemia - Dormant Projects, H2 2020 (Contd..1), H2 2020
Tularaemia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tularaemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020